The incidence and risk factors of invasive fungal infection after haploidentical haematopoietic stem cell transplantation without in vitro T-cell depletion

Clinical Microbiology and Infection

Volumn 18, Issue 10, 2012, Pages 997-1003

  Sun, Y Q ^a   Xu, L P ^a   Liu, D H ^a   Zhang, X H ^a   Chen, Y H ^a   Chen, H ^a   Ji, Y ^a   Wang, Y ^a   Han, W ^a   Wang, J Z ^a   Wang, F R ^a   Liu, K Y ^a   Huang, X J ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Haematopoietic stem cell transplantation; Invasive fungal infection

Indexed keywords

AMPHOTERICIN B; BUSULFAN; CASPOFUNGIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; FLUCONAZOLE; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; METHOTREXATE; MICAFUNGIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SIMUSTINE; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VORICONAZOLE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ARTICLE; CHILD; FEMALE; HAZARD RATIO; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IN VITRO STUDY; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; SYSTEMIC MYCOSIS; T CELL DEPLETION; TREATMENT OUTCOME;

EID: 84864525835     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03697.x     Document Type: Article

References (23)

1. Bow EJ. Invasive fungal infection in haematopoietic stem cell transplant recipients: epidemiology from the transplant physician's viewpoint. Mycopathologia 2009; 168: 283-297.
2. Huang X, Liu D, Liu K et al. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematologic malignancies in children. Biol Blood Marrow Transplant 2009; 15: 91-94.
3. Huang XJ, Liu DH, Liu KY et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006; 38: 291-297.
4. Lu DP, Dong L, Wu T et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006; 107: 3065-3073.
5. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
6. Przepiorka D, Weisdorf D, Martin P et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
7. Sullivan KM, Agura E, Anasetti C et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250-259.
8. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358-4366.
9. Aversa F, Reisner Y, Martelli MF. The haploidentical option for high-risk haematological malignancies. Blood Cells Mol Dis 2008; 40: 8-12.
10. Aversa F, Terenzi A, Tabilio A et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23: 3447-3454.
11. Lang P, Greil J, Bader P et al. Long-term outcome after haploidentical stem cell transplantation in children. Blood Cells Mol Dis 2004; 33: 281-287.
12. Jantunen E, Ruutu P, Niskanen L et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 1997; 19: 801-808.
13. Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 32: 1319-1324.
14. Kontoyiannis DP, Marr KA, Park BJ et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-associated Infection Surveillance Network (TRANSNET) database. Clin Infect Dis 2009; 50: 1091-1100.
15. Bolwell B, Pohlman B, Sobecks R et al. Prognostic importance of the platelet count 100 days post allogeneic bone marrow transplant. Bone Marrow Transplant 2004; 33: 419-423.
16. Ramirez P, Brunstein CG, Miller B, Defor T, Weisdorf D. Delayed platelet recovery after allogeneic transplantation: a predictor of increased treatment-related mortality and poorer survival. Bone Marrow Transplant 2010; 46: 981-986.
17. Kim DH, Baek JH, Kim JG et al. Clinical significance of platelet count at day +60 after allogeneic peripheral blood stem cell transplantation. J Korean Med Sci 2006; 21: 46-51.
18. Kim DH, Sohn SK, Jeon SB et al. Prognostic significance of platelet recovery pattern after allogeneic HLA-identical sibling transplantation and its association with severe acute GVHD. Bone Marrow Transplant 2006; 37: 101-108.
19. Chang YJ, Xu LP, Liu DH et al. Platelet engraftment in patients with hematologic malignancies following unmanipulated haploidentical blood and marrow transplantation: effects of CD34+ cell dose and disease status. Biol Blood Marrow Transplant 2009; 15: 632-638.
20. Grazziutti ML, Rex JH, Cowart RE, Anaissie EJ, Ford A, Savary CA. Aspergillus fumigatus conidia induce a Th1-type cytokine response. J Infect Dis 1997; 176: 1579-1583.
21. Hebart H, Bollinger C, Fisch P et al. Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies. Blood 2002; 100: 4521-4528.
22. Cornely OA, Bohme A, Reichert D et al. Risk factors for breakthrough invasive fungal infection during secondary prophylaxis. J Antimicrob Chemother 2008; 61: 939-946.
23. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-1821.